Inoperable Renal Malignant Glomus Tumor, the answers for all the “W’s”?

Pushkala Surianarayanan¹, Arun Ramdas Menon¹, Shirley Sundersingh², Anand Raja¹

¹Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India; ²Department of Onco-Pathology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

Abstract
Glomus tumor, arising from glomus bodies (specialized neurovascular structures involved in thermoregulation), commonly occurs in extremities and rarely in viscera. The spectrum of glomus tumors range from benign tumors to tumors with uncertain malignant potential to tumors of the malignant subtype. A vast majority of visceral glomus tumors are benign. Most common visceral tumors arise in the gastrointestinal tract. Glomus tumors of the kidney are a rare entity of which malignant glomus tumors are exceedingly rare. The index patients in the existing case reports were middle-aged males. We report our experience with malignant glomus tumor of the left kidney in a 60-year-old female, with computed tomography (CT) showing involvement of renal vein and inferior vena cava (IVC). Percutaneous biopsy was performed as imaging did not conform to the appearance of a conventional renal tumor and was reported as malignant glomus tumor after immunohistochemistry. After informed decision, the patient and family elected to proceed with surgery. However, intraoperatively, the left renal mass was found to infiltrate the pancreas, duodenum, aorta, and root of the colonic mesentery due to which surgery was aborted. Biopsy obtained intraoperatively again confirmed diagnosis of left renal malignant glomus tumor. She had an uneventful postoperative recovery. Options of treatment were reviewed by a multidisciplinary board. In light of no proven benefit for systemic therapy, she was referred for supportive care. She was under follow-up and she expired after 7 months due to progressive disease. Our literature review focuses on the clinicopathologic features and the current standard of management of malignant renal glomus tumors.

Keywords: Glomus tumor; Kidney; Glomangiosarcoma; Nephrectomy; pericytic tumor

Introduction
Glomus tumors are Pericytic (perivascular) tumors of mesenchymal origin that predominantly occur in extremities and rarely involve the viscera. The family of tumors includes myopericytoma, myofibroma, angioleiomyoma, and glomus tumors and their variants. In the extremities, the cell of origin is the glomus cell, which is involved in thermoregulation. In the visceral disease, perivascular myoid cells have been hypothesized as cell of origin. The spectrum of glomus tumors ranges from benign to malignant subtypes with
This showed fibroconnective tissue infiltrated by sheets of atypical cells showing moderate cytoplasm, hyperchromatic pleomorphic nuclei with inconspicuous nucleoli, suggesting a poorly differentiated malignant tumor (Figure 2A,C). Immunohistochemistry was positive for vimentin, smooth muscle actin (SMA), keratin, caldesmon and weakly positive for calponin, with 40% Ki 67 positivity, suggesting a diagnosis of malignant glomus tumor (Figure 2D,F). After informed decision, the patient and family elected to proceed with surgery. However, intraoperatively, the left renal mass was found to infiltrate the pancreas, duodenum, aorta, and root of the colonic mesentery due to which surgery was aborted. Biopsy obtained intraoperatively again confirmed diagnosis of left renal malignant glomus tumor. She had an uneventful post-operative recovery. Options of treatment were reviewed by the multidisciplinary board. In light of no proven benefit for systemic therapy, she was referred for supportive care. She was under follow-up and she expired after 7 months due to progressive disease.

Discussion

What are Glomus Tumors?

Glomus tumors are mesenchymal neoplasms belonging to the family of pericytic perivascular tumors, predominantly encountered in the extremities and less commonly in visceral

Figure 1: Computed tomography images showing the heterogeneously enhancing left renal mass involving the left renal vein and IVC and abutting the aorta. (A) Cross-sectional image and (B) Sagittal image. (T – Tumor), arrow pointing to the inferior vena cava (IVC) thrombus.
Case of inoperable malignant glomus tumor of the kidney, the answers to all the W’s?

Figure 2: (A–C) Sheets of round cells with moderate cytoplasm and hyperchromatic nuclei with interspersed vascular spaces. H&E 200×, (D) Tumor cells express vimentin. DAB 400×, (E) Tumor cells express smooth muscle actin. DAB 400X, (F) Tumor cells show high proliferative activity with Ki67. DAB 400× DAB - Diaminobenzene.

organs (1). They arise from Sucquet-Hoyer canal of glomus bodies, which are specialized neurovascular organs involved in thermoregulation. The vast majority of these tumors are benign, with rare reports of malignancy (1–3).

The predominant occurrence of glomus tumors in the extremities mirrors the distribution of glomus bodies, where they grossly appear as small well-circumscribed blue–red nodules usually located in the subungual region of the nail. Twenty-five percent of glomus tumors originate in the viscera, which is peculiar in that, glomus bodies are rarely found in the viscera (4). Involvement of the gastrointestinal tract, female genital tract, bone, mediastinum, trachea, heart, lymph nodes, and the kidney have been described (4, 5).

What makes renal glomus tumor different?

Primary renal glomus tumors are rare and have been reported to arise from the renal capsule, parenchyma, and from within the collecting system (4); however, the cell of origin is unknown. One hypothesis is that pericytic tumors are morphologically related to the differentiation of perivascular myoid cells that invest in blood vessels and function physiologically in vascular modification and thermoregulation.

Visceral glomus tumors may involve urologic organs like bladder, urethra commonly, and rarely the prostate (5, 6).

Majority of renal glomus tumors are benign. Primary malignant renal glomus tumors are exceedingly rare with only a handful of cases reported in literature (Table 1) (3). Our case is also noteworthy for the presence of an IVC thrombus.

What are the clinical characteristics of patients with renal glomus tumors?

Benign renal glomus tumors occur in the second to ninth decades of life, and in both genders (4). On the other hand, malignant renal glomus tumors have been reported in males in their 40s, with no prior reports in females. The clinical presentation is similar to those of any renal tumor, commonly an incidental diagnosis and rarely with flank pain or microscopic hematuria.

No distinctive characteristics have been described on imaging and are hence indistinguishable from other renal tumors, particularly when organ-confined. The tumor may show Standard Uptake Value (SUV) uptake in F18 Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) due to perivascular origin (7). Consequently, diagnosis has to be made primarily on extirpative pathology (4). Our patient presented with a large tumor that did not have the appearance of a conventional renal tumor, which prompted percutaneous biopsy.
What is the pathology of renal glomus tumors?

The spectrum of glomus tumors ranges from benign, tumors with uncertain malignant potential, to malignant glomus tumors, and is depicted in Figure 3. On microscopy, sheets and nests of small round cells with pale eosinophilic to amphophilic cytoplasm are seen in stroma, interspersed with vessels of varying sizes, ranging from small to large and ectatic. These tumors are classified as solid glomus tumor, glomangioma, or glomangiomyoma based on the varying predominance of neoplastic smooth muscle, vascular and stromal component (8), as described in Figure 3.

What are malignant glomus tumors?

Goud et al. (2) classified aggressive/potentially malignant glomus tumors based on their histologic appearance as:

- those arising from benign glomus tumors based on the presence of benign glomus cells in periphery
- those arising de novo, based on the absence of such benign glomus cells
- locally infiltrative glomus tumors (LIGT), i.e., invasive tumors without cytologic atypia (2).

Folpe et al. (1) proposed that the presence of clinical and histologic features like

- deep location,
- size > 2 cm,
- atypical mitotic figures

are commonly associated with malignant glomus tumors or glomus tumors with uncertain malignant potential. He has also reported the metastatic rate of malignant glomus tumors of dermal origin to be as high as 38% (1).

Our case fulfilled all criteria for suspicion of malignancy described above. Also, the presence of cytoplasmic actin and focal lattice work of collagen 4 has also been reported to indicate malignancy (9). On immunohistochemistry, unlike renal cell carcinoma, glomus tumors are negative for epithelial markers and markers native to renal origin like PAX8 (paired box gene 8)/AMACR (alpha-methylaceyl CoA race-mase)/CA IX (carbonic anhydrase IX). The tumor was positive for muscle markers like Smooth Muscle Actin (SMA), vimentin, keratin and caldesmon (10) (Table 2). The marker of proliferation Ki 67 was 30–40%.

P53-positive staining has been associated with malignant glomus tumors (11). B-raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations have been observed in malignant renal glomus tumors, which can be utilized as a potential tumor agnostic therapy (10).

What are familial glomus tumors?

Congenital familial multiple glomus tumors present with multifocal tumors, with incomplete penetrance, following autosomal dominant pattern of inheritance, due to inactivating mutation/uniparental disomy of Glomulin (GLMN) gene

![Figure 3: Spectrum of glomus tumor and clinicopathologic features of each subtype. HPF – high power field.](image-url)
located on Chromosome 1p22.1 or biallelic inactivation of neurofibromatosis 1 (NF1) gene. NOTCH2 re-arrangements are seen in 52% of glomus tumors (10).

What does the WHO classification of renal tumors 2022 say?
The updated WHO classification of renal tumors 2022, 5th edition (10) classifies renal glomus tumors into pericytic perivascular tumors of mesenchymal origin (as was earlier). The essential diagnostic criteria are the presence of round monomorphic cells with well-defined borders with diffuse positivity for muscle markers (smooth muscle actin, muscle-specific actin, caldesmon, calponin, pericellular collagen IV), and the desirable features are negative epithelial/vascular/melanoma markers. Because of the monotonous epithelioid morphology, low-grade clear cell carcinoma can be mimicked, especially in core needle biopsy specimens.

It mentions that the ability to metastasize is the only criterion for malignant glomus tumors, notwithstanding the histologic features that distinguish benign from malignant glomus tumors that have stood the test of time.

What are the differential diagnoses?
The differential diagnosis of primary renal glomus tumors includes renal epithelial tumors and other mesenchymal tumors. The latter include angiomyolipoma, juxtaglomerular cell tumor, hemangiomomas and leiomyoma, hemangiopericytoma, leiomyosarcoma with epithelioid change, and round cell tumors, such as rhabdomyosarcoma and Ewing’s Sarcoma/Primitive Neuroectodermal tumor (PNET). This is due to the histology of uniform monomorphic round cells. Differentiation is possible by characteristic histopathologic features and immunohistochemistry. No support cytogenetics findings have been reported to date. The immunohistochemistry (IHC) features are described in Table 2.

What is the frequency of recurrence?
Only one case has been reported to have recurred in the contralateral (left) kidney at 7 years after diagnosis with a locally infiltrative recurrence in the contralateral kidney after a nephron sparing approach at 9 years from initial diagnosis. It is noteworthy that this patient had a 16-cm right renal tumor fulfilling all criteria for a malignant glomus tumor. There is a theoretical possibility of familial multiple glomus tumor syndrome. Though the best possible chance of cure is by margin negative resection, follow-up of these patients is also important and one can extrapolate the follow-up schedule of conventional renal carcinoma to these patients until further guidelines emerge.

What is the treatment?
The treatment of benign glomus tumor is complete surgical excision, which, in case of glomus tumor of the kidney, involves radical nephrectomy, or partial nephrectomy, if feasible (4). Chen et al, hypothesized that due to the lack of a pseudo capsule or pericapsular inflammation, enucleation may lead to positive margins/recurrence (3). Despite this, excellent outcomes have been reported for benign lesions, with no recurrence (4). Majority of five out of six malignant glomus tumors reported to date have been relatively large compared to benign tumors with size ranging from 3.7 to –7.0 cm and have been managed with radical nephrectomy when organ-confined. One patient underwent partial nephrectomy (7), as the tumor size was 2.5 cm, margins were negative, and the patient was doing well at 15 months. A curative resection radical/nephron sparing with negative margins is of utmost importance in the management of these patients.

With follow-up ranging from 6 to 15 months, no recurrence has been reported in organ-confined malignant glomus tumors, suggesting that complete surgical excision is curative (5, 14, 16).

The role of active surveillance if a benign diagnosis is established unequivocally on percutaneous diagnosis is not known, although it is possible at least in theory.

Due to its rarity, limited data are available on the use of systemic therapy in locally advanced disease and metastatic disease. Prognosis is generally poor with survival ranging from 6 months to 3 years (1, 4). Radiation and gemcitabine use were associated with poor response (9). Modest response with delay in tumor growth has been reported with somatostatin and temozolomide (13).

The role of radiation is solely useful in a palliative setting to the metastatic sites like spine in cases with pain or impending malignant spinal cord compression.

Tumor agnostic therapy by use of BRAF inhibitors is yet to be studied but has a potential for opening a new horizon for therapy for patients with advanced disease.

What to do if there is a report of glomus tumor on histopathology?
Scenario 1 – nonmetastatic after nephron sparing procedure

Step 1 – risk stratification according to Folpe criteria (1)
Step 2 – check for margin status – absence of pseudo-capsule or peritumoral inflammation makes the tumor susceptible for positive margins in nephron-sparing approach
Step 3 – One can look for cytoplasmic actin and focal lattice work of collagen 4 which indicate malignancy in addition to Folpe criteria (as per WHO 2022, metastasis is the only indicator of malignant glomus tumor)
<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Author</th>
<th>Age/Sex</th>
<th>Size</th>
<th>Presentation</th>
<th>Site</th>
<th>Positive IHC</th>
<th>Management</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Gill (2010) (15)</td>
<td>46 Male</td>
<td>8.7 cm</td>
<td>Microscopic hematuria</td>
<td>Right kidney lower pole</td>
<td>SMA, MSA, vimentin, synaptophysin CD 34, BCL-2</td>
<td>Radical nephrectomy</td>
<td>NED at 15 months</td>
</tr>
<tr>
<td>2</td>
<td>Lamba (2010) (9)</td>
<td>44 Male</td>
<td>NA</td>
<td>Lower back pain due to vertebral metastasis</td>
<td>Right kidney, IVC thrombus</td>
<td>SMA, vimentin, collagen IV, CD 34</td>
<td>Radiation + one cycle gemcitabine, doxorubicin, dacarbazine Palliative radiation</td>
<td>Expired 6 months after diagnosis</td>
</tr>
<tr>
<td>3</td>
<td>Chen (2016) (5)</td>
<td>46 Male</td>
<td>4.5 cm</td>
<td>Incidental</td>
<td>Right kidney upper pole</td>
<td>NA</td>
<td>Radical nephrectomy</td>
<td>NED at 6 months</td>
</tr>
<tr>
<td>4</td>
<td>Lu (2016) (12)</td>
<td>46 Male</td>
<td>NA</td>
<td>Incidental</td>
<td>Right kidney upper pole</td>
<td>NA</td>
<td>Radical nephrectomy</td>
<td>NA</td>
</tr>
<tr>
<td>5A</td>
<td>Li (2018) (16)</td>
<td>31 Female</td>
<td>16 cm</td>
<td>Right flank pain</td>
<td>Right kidney</td>
<td>SMA, collagen IV</td>
<td>Right radical nephrectomy</td>
<td>Recurred in left kidney at 7 years, partial left nephrectomy done, recurred locoregionally after 2 years succumbs at 13 years</td>
</tr>
<tr>
<td>5B</td>
<td>Li (2018) (16)</td>
<td>33 Female</td>
<td>9.5 cm</td>
<td>Heart murmur (Tumor in the vegetation of tricuspid valve)</td>
<td>Left kidney</td>
<td>Vimentin, MSA</td>
<td>Radical nephrectomy, IVC thrombectomy</td>
<td>NA</td>
</tr>
<tr>
<td>6</td>
<td>Kapogiannis (2021) (11)</td>
<td>67 Male</td>
<td>2.5 cm</td>
<td>Incidental</td>
<td>Right kidney lower pole</td>
<td>SMA, CD57, vimentin</td>
<td>Partial nephrectomy</td>
<td>NED at 15 months</td>
</tr>
<tr>
<td>7</td>
<td>Nwanze (2021) (14)</td>
<td>32 Male</td>
<td>5.2 cm</td>
<td>Incidental</td>
<td>Right kidney lower pole</td>
<td>CD34, vimentin, SMA, caldesmon</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>8</td>
<td>Present case</td>
<td>60 Female</td>
<td>11 cm</td>
<td>Flank pain</td>
<td>Left kidney</td>
<td>SMA, Vimentin, caldesmon, calponin</td>
<td>Inoperable</td>
<td>Expired 7 months after diagnosis</td>
</tr>
</tbody>
</table>

SMA – Smooth Muscle Actin; MSA – Muscle Specific Actin; CD - Cluster of Differentiation; Bcl 2 – B cell lymphoma 2; NA – Not Applicable; IVC – Inferior Vena Cava; NED – No evidence of disease.
Table 2: Immunohistochemistry profile of our patient.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimentin</td>
<td>Positive</td>
</tr>
<tr>
<td>Smooth muscle actin (SMA)</td>
<td>Positive</td>
</tr>
<tr>
<td>Desmin</td>
<td>Negative</td>
</tr>
<tr>
<td>Muscle actin</td>
<td>Negative</td>
</tr>
<tr>
<td>Human melanoma black (HMB) 45</td>
<td>Negative</td>
</tr>
<tr>
<td>Melan A</td>
<td>Negative</td>
</tr>
<tr>
<td>S100P</td>
<td>Negative</td>
</tr>
<tr>
<td>CD 34</td>
<td>Negative</td>
</tr>
<tr>
<td>Inhibin</td>
<td>Negative</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Negative</td>
</tr>
<tr>
<td>Leukocyte common antigen</td>
<td>Negative</td>
</tr>
<tr>
<td>Multiple myeloma oncogene 1 (MUM 1)</td>
<td>Negative</td>
</tr>
<tr>
<td>CD 30</td>
<td>Negative</td>
</tr>
<tr>
<td>CD 99</td>
<td>Negative</td>
</tr>
<tr>
<td>Keratin</td>
<td>Occasional positive</td>
</tr>
<tr>
<td>C Kit</td>
<td>Negative</td>
</tr>
<tr>
<td>Activin receptor-like kinase-1 (ALK1)</td>
<td>Negative</td>
</tr>
<tr>
<td>Calponin</td>
<td>Weak positive</td>
</tr>
<tr>
<td>Caldesmon</td>
<td>Positive</td>
</tr>
</tbody>
</table>

CD – Cluster of Differentiation.

Step 4 – p53 and BRAF V600E testing can be desirable
Step 5 – Follow-up

Scenario 2 – advanced disease

Step 1 – curative resection offers the best possible chance for the patient
Step 2 – If inoperable, BRAF V 600E mutation can be tested for and targeted if present
Step 3 – Follow-up. Survival of 6 months to 24 months as per cases in the literature

Where do the advanced tumor spread?

On literature review, three cases were advanced, and two had tumor thrombus in the inferior vena cava (one had tumor in the vegetation of tricuspid valve). Infiltration to adjacent structures was noted in one tumor at presentation and in one recurrent tumor. One case had distant metastases to the vertebra. None of the cases had lymph node metastasis/metastasis to the lungs.

Conclusion

Malignant renal glomus tumor is a rare entity that is potentially curable by resection with negative margins. The pathology lays the basis of diagnosis. In advanced stages, the survival is poor with limited data for the use of conventional chemo- or radiotherapy. Tumor agnostic therapy can open up a brand new arena of scope in patients with advanced disease.

Ethics Statement

The authors certify that informed consent was obtained from the patient, and all related information was deidentified prior to publication.

References


